Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 49

1.

Differentially expressed microRNA-218 modulates the viability of renal cell carcinoma by regulating BCL9.

Wang J, Ying Y, Bo S, Li G, Yuan F.

Mol Med Rep. 2016 Aug;14(2):1829-34. doi: 10.3892/mmr.2016.5403. Epub 2016 Jun 15.

PMID:
27314976
2.

Association study of BCL9 gene polymorphism rs583583 with schizophrenia and negative symptoms in Japanese population.

Kimura H, Tanaka S, Kushima I, Koide T, Banno M, Kikuchi T, Nakamura Y, Shiino T, Yoshimi A, Oya-Ito T, Xing J, Wang C, Takasaki Y, Aleksic B, Okada T, Ikeda M, Inada T, Iidaka T, Iwata N, Ozaki N.

Sci Rep. 2015 Oct 23;5:15705. doi: 10.1038/srep15705.

3.

Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.

Elsarraj HS, Hong Y, Valdez KE, Michaels W, Hook M, Smith WP, Chien J, Herschkowitz JI, Troester MA, Beck M, Inciardi M, Gatewood J, May L, Cusick T, McGinness M, Ricci L, Fan F, Tawfik O, Marks JR, Knapp JR, Yeh HW, Thomas P, Carrasco DR, Fields TA, Godwin AK, Behbod F.

Breast Cancer Res. 2015 Sep 17;17:128. doi: 10.1186/s13058-015-0630-z.

4.

Common variants in the BCL9 gene conferring risk of schizophrenia.

Li J, Zhou G, Ji W, Feng G, Zhao Q, Liu J, Li T, Li Y, Chen P, Zeng Z, Wang T, Hu Z, Zheng L, Wang Y, Shen Y, He L, Shi Y.

Arch Gen Psychiatry. 2011 Mar;68(3):232-40. doi: 10.1001/archgenpsychiatry.2011.1.

PMID:
21383261
5.

BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells.

Mani M, Carrasco DE, Zhang Y, Takada K, Gatt ME, Dutta-Simmons J, Ikeda H, Diaz-Griffero F, Pena-Cruz V, Bertagnolli M, Myeroff LL, Markowitz SD, Anderson KC, Carrasco DR.

Cancer Res. 2009 Oct 1;69(19):7577-86. doi: 10.1158/0008-5472.CAN-09-0773. Epub 2009 Sep 8.

6.

Analysis of the interaction of BCL9 with beta-catenin and development of fluorescence polarization and surface plasmon resonance binding assays for this interaction.

Kawamoto SA, Thompson AD, Coleska A, Nikolovska-Coleska Z, Yi H, Wang S.

Biochemistry. 2009 Oct 13;48(40):9534-41. doi: 10.1021/bi900770z.

PMID:
19715304
7.

Overexpression and altered subcellular localization of autophagy-related 16-like 1 in human oral squamous-cell carcinoma: correlation with lymphovascular invasion and lymph-node metastasis.

Nomura H, Uzawa K, Yamano Y, Fushimi K, Ishigami T, Kouzu Y, Koike H, Siiba M, Bukawa H, Yokoe H, Kubosawa H, Tanzawa H.

Hum Pathol. 2009 Jan;40(1):83-91. doi: 10.1016/j.humpath.2008.06.018. Epub 2008 Sep 11.

PMID:
18789482
8.

Linkage and cytogenetic mapping of the BCL9 gene to porcine chromosome 4.

Knoll A, Dvorák J, Rohrer GA, Cepica S.

Anim Genet. 2002 Apr;33(2):162-3. No abstract available.

PMID:
12047235
9.

Fluorescence in situ hybridization analysis of chromosome 1 abnormalities in hematopoietic disorders: rearrangements of DNA satellite II and new recurrent translocations.

Busson-Le Coniat M, Salomon-Nguyen F, Dastugue N, Maarek O, Lafage-Pochitaloff M, Mozziconacci MJ, Baranger L, Brizard F, Radford I, Jeanpierre M, Bernard OA, Berger R.

Leukemia. 1999 Dec;13(12):1975-81.

PMID:
10602418
10.

Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21.

Willis TG, Zalcberg IR, Coignet LJ, Wlodarska I, Stul M, Jadayel DM, Bastard C, Treleaven JG, Catovsky D, Silva ML, Dyer MJ.

Blood. 1998 Mar 15;91(6):1873-81.

11.

BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via β-catenin pathway.

Zhang Y, Zhang Q, Chen H, Wang C.

Life Sci. 2018 Sep 1;208:284-294. doi: 10.1016/j.lfs.2018.07.023. Epub 2018 Jul 23.

12.

MEF2D-BCL9 Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents.

Suzuki K, Okuno Y, Kawashima N, Muramatsu H, Okuno T, Wang X, Kataoka S, Sekiya Y, Hamada M, Murakami N, Kojima D, Narita K, Narita A, Sakaguchi H, Sakaguchi K, Yoshida N, Nishio N, Hama A, Takahashi Y, Kudo K, Kato K, Kojima S.

J Clin Oncol. 2016 Oct 1;34(28):3451-9. doi: 10.1200/JCO.2016.66.5547. Epub 2016 Aug 9.

PMID:
27507882
13.

HIF-1α activates hypoxia-induced BCL-9 expression in human colorectal cancer cells.

Tan Z, Huang Q, Zang J, Teng SF, Chen TR, Wei HF, Song DW, Liu TL, Yang XH, Fu CG, Hu ZQ, Zhou W, Yan WJ, Xiao JR.

Oncotarget. 2017 Apr 18;8(16):25885-25896. doi: 10.18632/oncotarget.8834.

14.

BCL9/9L-β-catenin Signaling is Associated With Poor Outcome in Colorectal Cancer.

Moor AE, Anderle P, Cantù C, Rodriguez P, Wiedemann N, Baruthio F, Deka J, André S, Valenta T, Moor MB, Győrffy B, Barras D, Delorenzi M, Basler K, Aguet M.

EBioMedicine. 2015 Oct 30;2(12):1932-43. doi: 10.1016/j.ebiom.2015.10.030. eCollection 2015 Dec.

15.

miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway.

Zhao JJ, Lin J, Zhu D, Wang X, Brooks D, Chen M, Chu ZB, Takada K, Ciccarelli B, Admin S, Tao J, Tai YT, Treon S, Pinkus G, Kuo WP, Hideshima T, Bouxsein M, Munshi N, Anderson K, Carrasco R.

Cancer Res. 2014 Mar 15;74(6):1801-13. doi: 10.1158/0008-5472.CAN-13-3311-T. Epub 2014 Mar 5.

16.

BCL9 and C9orf5 are associated with negative symptoms in schizophrenia: meta-analysis of two genome-wide association studies.

Xu C, Aragam N, Li X, Villla EC, Wang L, Briones D, Petty L, Posada Y, Arana TB, Cruz G, Mao C, Camarillo C, Su BB, Escamilla MA, Wang K.

PLoS One. 2013;8(1):e51674. doi: 10.1371/journal.pone.0051674. Epub 2013 Jan 29.

17.

Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling.

Takada K, Zhu D, Bird GH, Sukhdeo K, Zhao JJ, Mani M, Lemieux M, Carrasco DE, Ryan J, Horst D, Fulciniti M, Munshi NC, Xu W, Kung AL, Shivdasani RA, Walensky LD, Carrasco DR.

Sci Transl Med. 2012 Aug 22;4(148):148ra117. doi: 10.1126/scitranslmed.3003808.

18.

MicroRNA-30c-2* expressed in ovarian cancer cells suppresses growth factor-induced cellular proliferation and downregulates the oncogene BCL9.

Jia W, Eneh JO, Ratnaparkhe S, Altman MK, Murph MM.

Mol Cancer Res. 2011 Dec;9(12):1732-45. doi: 10.1158/1541-7786.MCR-11-0245. Epub 2011 Oct 24.

19.

SOX7 Suppresses Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction.

Fan R, He H, Yao W, Zhu Y, Zhou X, Gui M, Lu J, Xi H, Deng Z, Fan M.

DNA Cell Biol. 2018 Feb;37(2):126-132. doi: 10.1089/dna.2017.3866. Epub 2017 Dec 22.

PMID:
29271667
20.

miR-1301 inhibits hepatocellular carcinoma cell migration, invasion, and angiogenesis by decreasing Wnt/β-catenin signaling through targeting BCL9.

Yang C, Xu Y, Cheng F, Hu Y, Yang S, Rao J, Wang X.

Cell Death Dis. 2017 Aug 17;8(8):e2999. doi: 10.1038/cddis.2017.356.

Supplemental Content

Support Center